X4 Pharmaceuticals (XFOR) Interest & Investment Income (2017 - 2026)

X4 Pharmaceuticals (XFOR) has reported Interest & Investment Income for 10 consecutive years, with $2.0 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Interest & Investment Income rose 197.59% year-over-year to $2.0 million; the trailing twelve-month figure through Jun 2026 stood at $7.0 million (up 44.37% YoY), and the FY2025 full-year result was $4.6 million, down 20.68% from the prior year.
• Interest & Investment Income declined to $2.0 million in Q2 2026 per XFOR's latest filing, from $2.1 million in the prior quarter.
• Across five years, Interest & Investment Income topped out at $2.1 million in Q1 2026 and bottomed at $3000.0 in Q1 2022.
• Historically, Interest & Investment Income has averaged $1.1 million across 5 years, with a median of $1.0 million in 2024.
• The sharpest annual moves came in 2023 and 2025: Interest & Investment Income soared 27733.33% in 2023, then slumped 57.51% in 2025.
• Over 5 years, Interest & Investment Income stood at $198000.0 in 2022, then soared by 629.8% to $1.4 million in 2023, then slipped by 12.32% to $1.3 million in 2024, then surged by 56.67% to $2.0 million in 2025, then fell by 0.3% to $2.0 million in 2026.
• According to Business Quant data, Interest & Investment Income over the past three periods registered $2.0 million, $2.1 million, and $2.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.